01 How it works
In lab and animal studies, BPC-157 encourages new blood vessels to grow into damaged tissue, helps the cells that rebuild tendons migrate into place, and dampens inflammation. Tendons and ligaments heal slowly mostly because they get so little blood — this is the gap it is thought to fill.
02 Common uses
03 Run profile
Start low and step up in phases. Taken once a day, five days on and two off — weekends off by default. Most runs last six to twelve weeks depending on the injury.
The profile shows the shape. Ask for the numbers for your vial, your goal and your timeline.
04 Pairs well with
05 What to watch for
Very little is commonly reported — mild irritation where you inject is the main one. Rotate sites and use clean technique. Redness or swelling that worsens after 48 hours, warmth, pus or fever need checking. Talk to a doctor first if you are pregnant, have a history of cancer, or take medication.
06 Evidence & status
Not approvedMost research is in animals and cell cultures; good human trials are scarce. The picture comes more from years of real-world use than from large studies.
Not FDA-approved. In July 2026 an FDA advisory panel voted 8–6 to recommend it for the 503A compounding list, a non-binding vote. On 28 October 2026 HHS issued an interim enforcement-discretion policy that lets state-licensed pharmacies and physicians compound single-ingredient BPC-157 (injected, oral or topical) while FDA rulemaking continues. It is still not on the 503A list, and there is no final FDA decision.
Sources
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewHSS Journal, 2025 · Review
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healingCell and Tissue Research, 2019 · Review
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeU.S. Food and Drug Administration, 2026 · Regulator document
- FDA Briefing Document, Pharmacy Compounding Advisory Committee (PCAC) Meeting, July 23-24, 2026U.S. Food and Drug Administration, 2026 · Regulator document
- FDA Advisory Committee's Vote May Open A Drug-Compounding Back Door For Unapproved PeptidesHealth Affairs Forefront, 2026 · Regulator document
- HHS Draft Policy Eases Enforcement on 6 Compounded PeptidesThe American Journal of Managed Care (AJMC), 2026 · Regulator document
- The Prohibited ListWorld Anti-Doping Agency, 2026 · Regulator document
Status and sources last checked November 3, 2026. Something out of date? Tell us.
07 How long until it works
There is no human trial that answers this. The 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 studies, of which 35 were in animals or cells and one in people. In the animal work, tendon and ligament repair measures improved over two to four weeks of daily dosing.
Real-world reports from people using it for tendon injuries tend to describe change on a similar timescale, which is why the run profile on this page is built around a six-to-twelve-week block. Treat that as the shape of common use, not a measured result. If a tendon injury is no better after eight weeks, that is a reason to see a sports medicine doctor, not to raise the dose.
08 BPC-157 vs TB-500
Both are “recovery” peptides and both rest on animal evidence. The difference people use to choose is reach. BPC-157 is usually taken for one specific site, a tendon, a ligament or the gut, and the animal literature is strongest for localised repair, where it promotes new blood-vessel growth into poorly supplied tissue.
TB-500, a fragment of thymosin beta-4, is taken for broader, whole-body recovery; thymosin beta-4 itself has been through early human trials, but for wounds and dry eye, not for the sports uses it is sold for. Neither has a human trial for tendon injury. They are often combined (the Wolverine Stack on this site), for which there is one exploratory animal study and no human data.
The TB-500 dossier →09 Stacking
The most common pairing is with TB-500, above. Some people add KPV for gut inflammation or GHK-Cu for skin. No published study has tested any of these combinations in people.
One practical note: the October 2026 HHS policy on compounded peptides covers single-ingredient products only, so a pharmacy cannot supply a combined vial under it.
10 Where it stands legally
BPC-157 is not approved by the FDA or any other major regulator. In July 2026 the FDA’s Pharmacy Compounding Advisory Committee voted 8–6 to recommend it for the 503A bulk substances list, against the advice of FDA’s own reviewers, who cited the lack of human safety data.
On 28 October 2026 HHS issued an interim policy saying it will not take enforcement action against state-licensed pharmacies and physicians compounding single-ingredient BPC-157 (injected, oral or topical) while the FDA’s rulemaking continues. That is a pause in enforcement, not an approval, and it can be withdrawn. For athletes: BPC-157 is named on WADA’s Prohibited List under S0, non-approved substances, so it is banned at all times in tested sport.
11 FAQ
How fast does it work?
Many people notice less pain within one to two weeks. Structural healing takes longer — that is why runs are measured in weeks.
Pen or vial?
The pen is pre-mixed and dial-dosed, the easier start. Vials are more flexible but you mix and measure yourself.
Can it be taken orally?
Oral forms exist and are mostly used for gut issues. For injuries, people generally inject.
Does BPC-157 work orally?
Animal studies have used it both injected and by mouth, and the HHS compounding policy covers oral BPC-157 as well as injected. There is no human study comparing the routes; most reported use for tendons is injected near the site.
Can BPC-157 cause cancer?
There is no evidence either way in people. Because it promotes blood-vessel growth in animal tissue, the usual advice is to avoid it with a history of cancer until someone has looked at the question properly. This is a theoretical concern, not a reported one.
Is BPC-157 banned in sport?
Yes. WADA lists it under S0, non-approved substances, so it is prohibited at all times for tested athletes.
Why does this page say “no human trials” when so many people use it?
Because use and evidence are different things. Years of real-world reports tell you what people experience; they do not tell you what the peptide did, or what happened to people who were not counted. That is why this page gives the schedule as common use, not as a tested dose.
Educational information only — not medical advice. The Daily Stack does not sell or supply any products. Talk to a licensed healthcare professional about your own health decisions.